Biomedical subjects

W H Yu

Publications and source records attributed to W H Yu.

At least 73 records · Page 4Linked to original sources

PubMed1996

Sensitive detection of metallothioneins-1, -2 and -3 in tissue homogenates by immunoblotting: a method for enhanced membrane transfer and retention.

Standard immunoblotting procedures were unable to detect metallothioneins-1 and 2 (MT-1, MT-2) and metallothionein-3 (MT-3)/growth inhibitory factor (GIF) in unfractionated brain homogenates. We have developed a novel process which involves the inclusion of 2 mM CaCl2 in electrophoretic transfer buffers and glutaraldehyde fixation following transfer to either nitrocellulose or polyvinylidene difluoride (PVDF) membranes. Using commercial MT antibodies and a specific MT-3 polyclonal antibody raised in our laboratory, we have been able to detect all three MTs on both membrane types with a detection limit of approx. 10 ng for MT-1 and MT-2. Nitrocellulose membrane pore size had no noticeable effect on detection sensitivity. These modifications enable more sensitive MT detection than previously described blotting methods. In addition, this technique eliminates the need for indirect monitoring approaches and simplifies quantification since sample fractionation or enrichment are not required.

Animals↗

PubMed1996

Is there VDAC in cell compartments other than the mitochondria?

Higher eukaryotes, including mammals and plants, express a family of VDAC proteins each encoded by a distinct gene. Two human genes encoding VDAC isoforms (HVDAC1 and HVDAC2) have been characterized in greatest detail. These genes generate three proteins that differ primarily by the addition of distinct N terminal extensions in HVDAC2 and HVDAC2', a splice variant of HVDAC2, relative to HVDAC1. Since N terminal sequences have been demonstrated to target many proteins to appropriate subcellular compartments, this observation raises the possibility that the N terminal differences found in HVDAC isoforms may lead to targeting of each protein to different cellular locations. Consistent with this hypothesis, a large number of reports have provided evidence consistent with the notion that HVDAC1 and its homolog in related mammalian species may specifically be present in the plasma membrane or other nonmitochondrial cellular compartments. Here, we review this information and conclude that if VDAC molecules are present at nonmitochondrial locations in mammalian cells, these are unlikely to be the known products of the HVDAC1 or HVDAC2 genes.

Animals↗

PubMed1996

The role of nitric oxide (NO) in control of hypothalamic-pituitary function.

Neurons containing neural nitric oxide synthase (nNOS) are found in various locations in the hypothalamus and, in particular, in the paraventricular and supraoptic nuclei with axons which project to the median eminence and extend into the neural lobe where the highest concentrations of NOS are found in the rat. Furthermore, nNOS is also located in folliculostellate cells and LH gonadotropes in the anterior pituitary gland. To define the role of NO in the release of hypothalamic peptides and pituitary hormones, we injected an inhibitor of NOS, Ng-monomethyl-L-arginine (NMMA) or a releasor of NO, nitroprusside (NP) into the third ventricle (3V) of conscious castrate rats and determined the effect on the release of various pituitary hormones. In vitro, we incubated medial basal hypothalamic (MBH) fragments and studied inhibitors of NO synthase and also releasors of NO. The results indicate that NOergic neurons play an important role in stimulating the release of corticotrophin-releasing hormone (CRH), luteinizing hormone releasing-hormone (LHRH), prolactin-RH's, particularly oxytocin, growth hormone-RH (GHRH) and somatostatin, but not FSH-releasing factor from the hypothalamus. NO stimulates the release of LHRH, which induces sexual behavior, and causes release of LH from the pituitary gland. The intrahypothalamic pathway by which NO controls LHRH release is as follows: glutamergic neurons synapse with noradrenergic terminals in the MBH which release nonepinephrine (NE) that acts on alpha 1 receptors on the NOergic neuron to increase intracellular free Ca++ which combines with calmodulin to activate NOS. The NOS diffuses to the LHRH terminal and activates guanylate cyclase (GC), cyclooxygenase and lipoxygenase causing release of LHRH via release of cyclic GMP, PGE2 and leukotrienes, respectively. Alcohol and cytokines can block LHRH release by blocking the activation of cyclooxygenase and lipoxygenase without interfering with the activation of GC. GABA also blocks the response of the LHRH neurons to NO and recent experiments indicate that granulocyte macrophage colony-stimulating factor (GMCSF) blocks the response of the LHRH neuron to NP by activation of GABA neurons since the blockade can be reversed by the competitive inhibitor of GABAa receptors, bicuculine.

Adrenocorticotropic Hormone↗

PubMed1995

Subcellular localization of human voltage-dependent anion channel isoforms.

The voltage-dependent anion channel of the outer mitochondrial membrane, VDAC (also known as mitochondrial porin), is a small abundant protein which forms a voltage-gated pore when incorporated into planar lipid bilayers. This protein forms the primary pathway for movement of major metabolites through the outer membrane. Recently, it has been demonstrated that two human VDAC genes, HVDAC1 and HVDAC2, produce three proteins that differ most significantly at their amino termini. These results suggest that the distinct amino termini lead to the targeting of individual VDAC isoforms to different cellular compartments. Consistent with this hypothesis, recent reports suggest that HIV-DAC1 is found in the plasma membrane of mammalian cells. To define the subcellular location of HVDAC isoforms, HVDAC genes were modified so that the encoded proteins contain COOH-terminal epitopes recognized by either of two monoclonal antibodies. Introduction of these epitope tags had no effect on the function of modified VDAC proteins. Epitope-tagged proteins were then individually expressed in COS7 cells or rat astrocytes and the intracellular location of each isoform subsequently identified by subcellular fractionation, light level immunofluorescence, and immunoelectron microscopy. Our results demonstrate that each HVDAC protein is exclusively located in fractions or subcellular regions containing mitochondrial marker proteins. In addition, immunofluorescence and immunoelectron microscopy show that an individual mitochondrion can contain both HVDAC1 and HVDAC2. Our results call into question previous reports demonstrating VDAC molecules in the plasma membrane and suggest that functional differences between individual VDAC isoforms may result in distinct regulatory processes within a single mitochondrion.

Amino Acid Sequence↗

PubMed1995

Age-related changes in androgen receptor levels in cranial nerve nuclei of male rats.

Sensory and motor events are important for mating, and several cranial nerve nuclei mediating these events contain androgen receptors (AR). Since mating behavior declines with age, we tested whether AR binding is decreased in cranial nerve nuclei of old male rats. Cytosol and cell nuclear androgen receptor (AR) binding was assessed in the cochlear, hypoglossal and facial nuclei in young (4 months) and old (20 months) male Fischer 344 rats. For comparison with other neural and non-neural tissue, AR binding in combined hypothalamus, preoptic area and amygdala (HPA), and muscle tissue from tongue and masseter were examined. Cytosol AR binding was significantly decreased in all three cranial nerve nuclei of old males. No age-related changes were observed in HPA or muscle. Cell nuclear AR binding was unaffected by age in all of the tissues analyzed. Neuron numbers in motor nuclei of the hypoglossal, facial and trigeminal nerves were compared between young and old rats. A significant decrease in neuron number was found only in the hypoglossal nucleus of old rats, indicating that neuronal loss is not a factor in the reduction of AR's in cranial nerve nuclei. It is suggested that the loss of AR's in cranial nerve nuclei of old rats contributes to the decline in male copulatory behavior by reducing responsiveness to sensory and motor cues.

Aging↗

PubMed1995

Glutamic acid induces luteinizing hormone releasing hormone release via alpha receptors.

Glutamic acid (GA) and norepinephrine (NE) stimulate luteinizing hormone-releasing hormone (LHRH) release via release of nitric oxide (NO) from NOergic neurons in the arcuate-median eminence region. To determine if GA releases LHRH via direct stimulation of NOergic neurons, or via stimulation of noradrenergic terminals, arcuate median eminence explants from male rats were incubated with various compounds, and the LHRH release into the medium was measured. GA-induced release of LHRH was completely blocked by phentolamine (1 microM), an alpha receptor blocker, which, by itself, had no effect on the release. Nitroprusside (NP), which spontaneously releases NO, more than doubled LHRH release. To determine if alpha receptors on the LHRH neuron are required for the action of NP, the tissue was incubated with phentolamine, plus NP. Phentolamine had no effect on the LHRH-releasing action of NP. The results are interpreted to mean that GA activates the release of NE from the noradrenergic terminals. This acts on alpha receptors on the NOergic neuron to produce the release of NO. This NO diffuses to the LHRH terminals and induces release of LHRH.

Amino Acid Oxidoreductases↗

PubMed1994

Rates of protein synthesis in the regenerating hypoglossal nucleus: effects of testosterone treatment.

Rates of protein synthesis (ICPSleu) along the entire rostral to caudal extent of the hypoglossal nucleus were determined in adult, female rats with the quantitative autoradiographic L-[1-14C]leucine method two and five weeks after unilateral hypoglossal axotomy with and without chronic treatment with testosterone. Rates of protein synthesis were increased on the axotomized side, and the increases were greater in the rostral portion of the nucleus at both time points examined. The effects of axotomy on ICPSleu were less at five weeks post-axotomy than at two weeks. In spite of the fact that testosterone has been shown to accelerate both the rate of outgrowth of regenerating cranial motor nerves (Kujawa et al., J. Neurosci. 11:3898-3906, 1991) and the recovery of function (Kujawa et al., Exp. Neurol. 105:80-85, 1989) and to attenuate the loss of neurons (Yu et al., Exp. Neurol. 80:349-360, 1983) there were no effects of testosterone on 1CPSleu in the hypoglossal nucleus in either sham-operated or axotomized rats.

Animals↗

PubMed1994

Effects of alpha-inhibin-92 fragments and alpha-inhibin-92 antiserum on the control of follicle-stimulating hormone release in male rats.

Alpha-inhibin-92 (alpha-IB-92) has been characterized from human seminal plasma and found to be active in suppressing FSH release in vitro and in vivo. In order to determine if smaller fragments of this 92 amino acid peptide would still be active to suppress FSH release, we have evaluated 5 of these fragments for their effects on FSH and LH release in the present study. Five alpha-IB-92 fragments (1-34, 1-46, 35-65, 35-92 and 66-92) were synthesized and injected intravenously (iv) into castrated adult rats (2 days post operation). Only fragments alpha-IB-92-(35-65) and alpha-IB-92-(66-92) significantly lowered plasma FSH, but not LH, at doses of 10 micrograms. These fragments exerted a preferential FSH-suppressing effect, but their activities were less than that of alpha-IB-92. In view of the rapid action of these peptides and the preferential FSH suppressing effect, they could be useful clinically to suppress FSH release. To determine the possible physiologic significance of alpha-IB-92, we injected antiserum raised against alpha-IB-92 into immature male rats and evaluated its effects on FSH and LH release. Normal rabbit serum (NRS) or anti-alpha-IB-92 serum was injected iv through indwelling jugular catheters into conscious, unrestrained 18 day-old male rats. Blood samples (0.2 ml) were collected at various intervals. Intravenous injection of alpha-IB-92 antiserum (0.1 ml/rat) selectively elevated plasma levels of FSH but not LH from 2-8 h post-injection in 18 day-old male rats (P < 0.01). Since immunoneutralization of alpha-IB-92 significantly elevated FSH release in immature rats, alpha-IB-92 has a physiological inhibiting role in control of FSH but not LH release at this stage of development.

Animals↗

PubMed1994

Nitric oxide synthase in motor neurons after axotomy.

Nitric oxide synthase (NOS), an enzyme involved in synthesis of nitric oxide (NO), has been localized in many diverse cell types. In the CNS and PNS, discrete neuron cell groups express NOS constitutively. Recent evidence indicates that NOS is inducible in neurons normally not expressing NOS. After transection of peripheral nerves, NOS expression was significantly up-regulated in the axotomized sensory ganglion cells, whereas in the corresponding motor neurons NOS was not induced unless axon regeneration was prevented and ensuing neuron death became massive. Studies on axotomy-induced NOS have been limited largely to spinal nerves, with only one reported in the vagus nerve. The aim of this study was to determine whether NOS induction in motor neurons of the brainstem after axotomy is regulated in a manner similar to that of the spinal cord. By NADPH-diaphorase histochemistry and NOS immunocytochemistry, the status of NOS in neurons of the hypoglossal nucleus, dorsal motor nucleus of the vagus, and motor nucleus of the facial nerve was examined 2 weeks after unilateral transection of the respective cranial nerves, and the results were compared with those of spinal motor neurons after transection of the sciatic nerve. NOS, undetectable in neurons of the three cranial motor nuclei of sham-operated animals, was observed in about 30-50% of neurons in the cranial motor nuclei ipsilateral to axotomy, but it was not detected in spinal motor neurons after axotomy. NOS localized in axotomized cranial motor neurons was unrelated to NOS of macrophages or endothelial cells. There was no appreciable cell loss from axotomy at this period except in the dorsal motor nucleus of the vagus, where some loss was observed. The results indicate that there is a fundamental difference in the regulation of NOS expression between motor neurons of the cranial and spinal nerves. The possible role of NOS/NO acting as cytoprotective or cytotoxic agent on injured motor neurons is discussed. Motor neurons of cranial and spinal nerves may serve as a useful model to further define the roles of NOS/NO in neurons, especially after traumatic injury.

Amino Acid Oxidoreductases↗

PubMed1993

Control of follicle-stimulating hormone and luteinizing hormone release by hypothalamic peptides.

Lesion, stimulation, and pharmacological studies point to separate hypothalamic control of pulsatile FSH and LH secretion. LH release is controlled by a region extending from the preoptic area to the anterior and mid-median eminence, whereas FSH release is controlled by a region extending from the dorsal anterior hypothalamic area to the caudal median eminence. We have separated an FSH-releasing factor from LHRH by gel-filtration on Sephadex G-25, confirming results obtained over 25 years ago; and we are attempting its isolation in collaboration with Vale and River. In the meantime, reasoning that FSH-releasing factor might be related to LHRH, we tested many analogs of LHRH and found one that has selective FSH-releasing activity over a 50-fold dose range; however, it is relatively weak. This led us to the possibility that the GAP might be FSH-RF. Indeed, GAP1-13 has FSH but no LH-releasing activity over a 100-fold dose range; however, it is less potent than we would expect of the natural product. Substituting D-Trp-9 into the molecule to inhibit enzymatic degradation yielded a more potent and completely selective FSH-releasing peptide,24 which could be clinically useful. Alpha-inhibin-92 of Li et al. has been shown to have a highly selective dose-related suppressive action on FSH release in castrate male rats.25 Smaller fragments (35-65 and 66-92) of this molecule also possess the activity, albeit at higher doses. That this molecule may be physiologically significant is indicated by elevations in plasma FSH in immature rats obtained following intravenous injection of antisera raised against the peptide. Because of its much smaller size than that of 32-kDa alpha, beta inhibins and the lack of carbohydrate in the molecule, this can be relatively easily synthesized and might have clinical utility as an FSH release-inhibiting peptide.

Animals↗

PubMed1993

Cloning and functional expression in yeast of two human isoforms of the outer mitochondrial membrane channel, the voltage-dependent anion channel.

The voltage-dependent anion channel (VDAC) of the outer mitochondrial membrane is a small abundant protein found in all eukaryotic kingdoms which forms a voltage-gated pore when incorporated into planar lipid bilayers. VDAC is also the site of binding of the metabolic enzymes hexokinase and glycerol kinase to the mitochondrion in what may be a significant metabolic regulatory interaction. Recently, there has been speculation that there may be multiple forms of VDAC in mammals which differ in their localization in the outer mitochondrial membrane and in their physiological function. In this report, we describe the identification and characterization of two human cDNAs encoding VDAC homologs (HVDAC1 and HVDAC2). To confirm VDAC function, each human protein has been expressed in yeast lacking the endogenous VDAC gene. Human proteins isolated from yeast mitochondria formed channels with the characteristics expected of VDAC when incorporated into planar lipid bilayers. In addition, expression of the human proteins in such strains can complement phenotypic defects associated with elimination of the endogenous yeast VDAC gene. Since VDAC is the site of binding of hexokinase to the outer mitochondrial membrane, the binding capacity of each VDAC isoform expressed in yeast mitochondria was assessed. When compared with the binding of hexokinase to mitochondria lacking VDAC, the results show that mitochondria expressing HVDAC1 are capable of specifically binding hexokinase, whereas mitochondria expressing HVDAC2 only bind hexokinase at background levels. The expression of each human cDNA has been assessed by Northern blot and polymerase chain reaction techniques. With one exception, each is expressed in all human cell lines and tissues examined.

Amino Acid Sequence↗

PubMed1992

Testosterone fails to rescue motoneurons from axotomy-induced death in young rats.

This study was undertaken to determine whether testosterone acting on muscle alone could enhance motoneuron survival after axotomy. Facial nerves were transected unilaterally in 10-day old rats in which androgen receptors were already present in skeletal muscle but not yet developed in motoneurons. Testosterone treatment lessened chromatolysis but failed to reduce neuronal loss which reached more than 50% 2 weeks postaxotomy. The inefficacy of testosterone was attributed to the death of motoneurons before they could re-establish synaptic contact with targets, thereby rendering target-derived trophic substances stimulated by testosterone unable to rescue motoneurons in a timely manner. The present finding is consistent with our hypothesis that functional neuromuscular connectivity is a prerequisite for testosterone to promote neuronal survival.

Animals↗

PubMed1991

Muscle as the primary site for testosterone to promote survival of axotomized motoneurons.

Whether the effect of testosterone to promote neuronal survival is expressed through its interaction with motoneurons or with effector muscles was investigated, since androgen receptors are present in both tissues. Following unilateral transection of the hypoglossal and facial nerves, hydroxyflutamide, an androgen receptor antagonist, was injected into the tongue muscles to block androgen receptor binding during the period when rats were treated with testosterone. The results indicate that hydroxyflutamide abolished testosterone effects on the hypoglossal but not the facial motor nucleus, indicating that androgen receptors in effector muscles are the primary mediators of hormonal actions. We postulate that testosterone may play a role in the production of muscle-derived factors which promote the survival of injured motoneurons.

Anesthesia↗

PubMed1991

Feedback of follicle-stimulating hormone to inhibit luteinizing hormone and stimulate follicle-stimulating hormone release in ovariectomized rats.

Injection of ovine follicle-stimulating hormone (o-FSH) into the third cerebral ventricle significantly suppressed plasma luteinizing hormone (LH) release in conscious, unrestrained ovariectomized rats. Intraventricular injection of o-FSH (0.5 microgram) significantly lowered the plasma levels of LH by 70 min and decreased pulse frequency, whereas the pulsatile release of FSH was unchanged during the 180-min duration of the experiment. In a 12-hour experiment, the suppression of LH release reached the maximum within 3 h (p less than 0.001), followed by a return of plasma LH level to initial values 6-8 h after intraventricular injection of o-FSH at doses of 0.5, 4 and 8 micrograms. Plasma levels of FSH were not significantly changed by the low dose of o-FSH (0.5 microgram), but there was a delayed elevation of plasma FSH during the 8-12 h after intraventricular injection of o-FSH at higher doses (4 and 8 micrograms). On the other hand, plasma prolactin was unchanged after intraventricular injection of o-FSH. Since the pituitary responsiveness to synthetic LH-releasing hormone (LHRH) was unimpaired at the end of the sampling and incubation with o-FSH suppressed the release of LHRH from median eminence terminals, these data indicate that FSH acts intrahypothalamically to suppress LHRH release. The late elevation of plasma FSH may be the result of enhanced release of FSH-releasing factor or of a delayed, direct effect of the hormone on the gonadotropes to increase release of FSH.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

PubMed1991

Roles of somatostatin and growth hormone-releasing factor in ether stress inhibition of growth hormone release.

In order to evaluate the release of somatostatin (SRIF) and growth hormone-releasing factor (GRF) into the pituitary gland in response to ether stress, a push-pull perifusion (PPP) technique has been used in freely moving rats. Push-pull cannulae (PPC) were implanted into the anterior pituitary (AP) glands of male rats. After a 7-day recovery period the rats were fitted with indwelling jugular catheters. The next day the animals were subjected to PPP of the AP during 1 h followed by ether stress (2 min) and another hour of perifusion. The perifusion flow was 20 microliters/min and 10-min fractions were collected and assayed for SRIF and GRF by RIA. Plasma growth hormone (GH) levels were assayed every 10 min. At the end of the experiments, the accuracy of PPC tip placements was ascertained with a dissecting microscope. Under basal conditions there were 2.9 pulses/h of SRIF with an amplitude of 12.76 +/- 0.46 pg. The output of SRIF and GRF in the 10-min period beginning with application of ether was increased 2-fold (p less than 0.005 and p less than 0.01, respectively). Interestingly, the increased release of SRIF continued for an additional 10 min, whereas GRF output decreased and was almost undetectable. The release of both GRF and SRIF had returned to basal values 20-30 min after stress. Mean plasma GH levels were significantly lowered 10 min after stress. Each of the 9 animals showed a restoration of pulsatile GH release to basal levels within 20-30 min after stress. Our findings provide compelling evidence that SRIF plays a prominent role in stress-induced inhibition of GH release in the rat by blocking the response to the transient elevation of GRF and continuing to suppress GH release for 20 min.

Animals↗

PubMed1991

[Anti-ulcer effect of anisodamine in rats].

Anisodamine, an analog of atropine, was isolated first in China. Anisodamine 12.5, 25, 50 mg.kg-1 ig protected the gastric mucosal damage induced by indomethacin, restraint, pyloric ligation or absolute ethanol in rats. Pretreatment with anisodamine 25 mg.kg-1 ig bid for 3 d decreased the incidence of ulcers in all of these models. The inhibitory rates were 27.4%, 75.9%, 80% and 65.4%, respectively. The secretion and activity of pepsin, the content of hexosamine in gastric tissue, the production of malondialdehyde and activity of superoxide dismutase were not affected by anisodamine except the secretion of gastric acid. It increased output of basal bicarbonate from 0.255 +/- 0.01 to 0.285 +/- 0.01 mumol.min-1 (P less than 0.05) and pH of content of stomach from 4.3 +/- 0.3 to 5.1 +/- 0.5 (P less than 0.05) when given by anisodamine 20 mg.kg-1 ig. It is apparent that both the inhibition on gastric acid secretion and augmentation of basal bicarbonate content of stomach are related to anti-ulcer effect of anisodamine.

Animals↗

PubMed1990

Common denominators in the etiology and pathology of visceral lesions of cystic fibrosis and Keshan disease.

The common denominator of a unique disseminated multi-focal miliary myocardial hyaline necrosis and fibrosis in Keshan disease (KSD) and cystic fibrosis (CF) and a commonality of the affected age groups of fetuses and preschool children led to the review of existing KSD autopsy material to search for pancreatic and hepatic lesions considered pathognomonic for CF. Pancreatic lesions considered pathognomonic for CF were found in 595, or 35% of 1700 documented cases of KSD. The pancreatic lesions were limited to tissues of fetuses and preschool children. Adults dying of KSD had diagnostic lesions limited to the cardiovascular system, liver, and skeletal muscle. Varying degrees of focal biliary cirrhosis were identified in 850, or 50% of the KSD autopsies, and 85, or 5% developed severe lobular cirrhosis. The common denominator in CF and KSD appears to be a primary or induced secondary selenium deficiency in age-susceptible humans, prenatally at or around 22 wk of fetal life, during early postnatal life, or during the rapid-growth preschool years. The basic difference between the natural history of CF and KSD is that the selenium deficiency is totally environmental in KSD and appears to be the result of a maternal malabsorptive syndrome or an abnormality of selenium transfer in CF.

Adult↗

PubMed1990

Selective FSH-releasing activity of [D-Trp9]GAP1-13: comparison with gonadotropin-releasing abilities of analogs of GAP and natural LHRHs.

We had previously shown that fragments of human gonadotropin-releasing hormone associated peptide (GAP) stimulated FSH and LH release in vivo. In particular, GAP1-13 had a preferential FSH-releasing activity. To decrease enzymatic degradation, analogs of GAP1-13 with D-amino acid substitutions were synthesized. The activities were tested in ovariectomized, estrogen-progesterone primed (OEP) rats and compared with those of GAP1-13, mammalian (m), chicken II (cII), and lamprey (1) LHRH. The peptides were injected (IV) into conscious, OEP rats and blood samples were obtained via the jugular catheter. [D-Trp9 )GAP1-13 selectively stimulated FSH release at a dose of 1 microgram. Multiple injections of this analog (10 micrograms every 30 min for 5 injections) induced a marked elevation of plasma FSH values which peaked (p less than 0.001) after the third injection. By contrast, [D-Trp9]GAP1-13 had no effect on LH and prolactin (PRL) release after either single or multiple injections. These doses of [D-Ala4]GAP1-13 had no effect on the release of FSH, LH or PRL. Both human GAP1-13 and its [D-Trp9] analog exerted a selective FSH-releasing effect at a dose of 10 micrograms, however, the [D-Trp9] analog was more potent than GAP1-13 on FSH release. The potency of [D-Trp9]GAP1-13 in releasing FSH was approximately 1/100th that of mLHRH. Chicken II LHRH had slightly selective FSH-releasing activity with a potency 1/10th that of mLHRH. Lamprey LHRH had a preferential LH-releasing activity and a potency 1000 times less than mLHRH. In conclusion. [D-Trp9]GAP1-13 is a selective FSH-releasing peptide of potential clinical value.

Animals↗